Meeting
2019 Genitourinary Cancers Symposium
Preliminary results of phase I clinical trial of high doses of seleno-L-methionine (SLM) in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.
Authors
Rohan Garje
University of Iowa, Iowa City, IA
Rohan Garje , James A. Brown , Kenneth Gerard Nepple , Laila Dahmoush , Andrew Bellizzi , Jaime Bonner , Sarah L Mott , Gideon Zamba , Douglas Earl Laux , Mohammed M. Milhem , Youcef M. Rustum , Yousef Zakharia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT02535533
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 660)
DOI
10.1200/JCO.2019.37.7_suppl.660
Abstract #
660
Poster Bd #
J13
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Phase1 clinical trial of high doses of Seleno-L-methionine (SLM), in sequential combination with axitinib in previously treated and relapsed clear cell renal cell carcinoma (ccRCC) patients.
First Author: Yousef Zakharia
Poster
2021 Genitourinary Cancers Symposium
Phase I with expansion clinical trial of seleno-l-methionine (SLM) in combination with axitinib in patients with relapsed clear cell renal cell carcinoma (ccRCC): Bench to bedside.
First Author: Yousef Zakharia
Poster
2022 ASCO Annual Meeting
Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.
First Author: Renee Maria Saliby
Poster
2019 Genitourinary Cancers Symposium
A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naïve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.
First Author: Saby George